Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Sane

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|December 15, 1989
Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and managementD C Sane, R M Califf, E J Topol, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 4, 2000
A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimeticsW Wang, G Camenisch, D C Sane, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapyD C Sane, N J Gresalfi, L A Enney-O'Mara, et al.
European Journal of Heart Failure|August 19, 2003
Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirinV L Serebruany, A H Glassman, A I Malinin, et al.
Journal of the American College of Cardiology|July 18, 2000
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapyD C Sane, L V Damaraju, E J Topol, et al.
Journal of the American College of Cardiology|March 15, 1994
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study GroupR A Harrington, D C Sane, R M Califf, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Thrombosis and Haemostasis|March 4, 1991
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarctionD C Sane, D C Stump, E J Topol, et al.
Circulation|January 1, 1991
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study GroupD C Sane, D C Stump, E J Topol, et al.
Circulation|August 22, 2001
Abciximab readministration: results of the ReoPro Readministration RegistryJ E Tcheng, D J Kereiakes, A M Lincoff, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|December 15, 1989
Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and managementD C Sane, R M Califf, E J Topol, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 4, 2000
A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimeticsW Wang, G Camenisch, D C Sane, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapyD C Sane, N J Gresalfi, L A Enney-O'Mara, et al.
European Journal of Heart Failure|August 19, 2003
Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirinV L Serebruany, A H Glassman, A I Malinin, et al.
Journal of the American College of Cardiology|July 18, 2000
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapyD C Sane, L V Damaraju, E J Topol, et al.
Journal of the American College of Cardiology|March 15, 1994
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study GroupR A Harrington, D C Sane, R M Califf, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Thrombosis and Haemostasis|March 4, 1991
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarctionD C Sane, D C Stump, E J Topol, et al.
Circulation|January 1, 1991
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study GroupD C Sane, D C Stump, E J Topol, et al.
Circulation|August 22, 2001
Abciximab readministration: results of the ReoPro Readministration RegistryJ E Tcheng, D J Kereiakes, A M Lincoff, et al.
Pageof 6